AstraZeneca’s Imfinzi Fails Again In Head And Neck Cancer
KESTREL Follows EAGLE To Crash Land
The Phase III KESTREL study evaluating Imfinzi missed its primary overall survival benefit and a key secondary outcome in first-line recurrent or metastatic head and neck squamous cell carcinoma.
You may also be interested in...
The latest failure of the combination of AZ's PD-L1 inhibitor and its CLTA4 inhibitor is in advanced head and neck cancer. It follows recent failures of the MYSTIC and ARCTIC trials in lung cancer.
The impact of the coronavirus pandemic on the size of the pharma R&D pipeline in 2020 could be felt in a number of ways.
AstraZeneca’s CEO Pascal Soriot confirmed the death of distinguished cancer researcher and head of its oncology R&D unit, José Baselga, on 21 March.